Topic: Cell Therapy

Two senators have introduced a bill designed to encourage deals that would allow insurers to spread payments for expensive therapies over time.

Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.

Novartis is looking ahead to China for introduction of its CAR-T treatment Kymriah with a deal for manufacturing there.

Eisai and Celgene veteran Michael Amoroso will take on the challenge of making Gilead's entrance into CAR-T cancer treatments a success.

The decision by Lonza to move cell-therapy work out of a U.S. facility that was hit by an FDA warning letter will cost the plant about 125 jobs.

Astellas buys Universal Cells, Teva is affected by Celltrion's manufacturing problem, Korea rolls out a digital health initiative.

New FDA commissioner Scott Gottlieb will build on progress the FDA was making in facilitating faster drug approvals, three biotech execs predicted.

Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.